BeOne Newsroom
Media Resources
Corporate Press Kits
Review resources about BeOne, formerly BeiGene.
Product & Pipeline Media Resources
Find information about our approved medicines and pipeline molecules.
Media Library
View and download images of our leaders, facilities, company logo and other corporate assets.
Press Releases
Read our latest news.
-
October 28, 2025
BeOne Medicines to Present at Upcoming Investor Conferences — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it…
-
October 28, 2025
BeOne Medicines to Present at Upcoming Investor Conferences — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it…
-
October 22, 2025
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6 — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its…
-
October 22, 2025
BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6 — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its…
-
October 20, 2025
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 — New data from two pivotal TEVIMBRA studies – RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in…
-
October 20, 2025
BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025 — New data from two pivotal TEVIMBRA studies – RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in…
-
October 13, 2025
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA — Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory…
-
October 13, 2025
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA — Breakthrough designation based on early, positive results of a Phase 1/2 study of sonrotoclax in patients with relapsed or refractory…
-
August 29, 2025
BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL) — Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high…
-
August 27, 2025
European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025 — Final analysis of RATIONALE-315 demonstrates clear overall survival benefit in perioperative setting in resectable non-small cell lung cancer Broad EU…
-
August 26, 2025
BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference — SAN CARLOS, Calif.–(BUSINESS WIRE)– BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it…
-
August 25, 2025
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million — Royalty Pharma to acquire rights to BeOne’s royalties on IMDELLTRA® (tarlatamab-dlle) worldwide (ex-China) sales for up to $950 million IMDELLTRA…
Congress Hub
Review the latest information about the data we’re presenting and where you can find us.
Responsible Business & Sustainability Report
Responsible Business & Sustainability is at the core of everything we do to positively impact the lives of patients and society.
Explore More
Our Pipeline
Our broad and deep cancer pipeline is one of the largest in the industry.